Literature DB >> 8190290

An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type.

I G McKeith1, A F Fairbairn, R A Bothwell, P B Moore, I N Ferrier, P Thompson, R H Perry.   

Abstract

Several recent autopsy studies suggest that senile dementia of Lewy body type (SDLT) may be the second most common neuropathologic cause of dementia in the elderly, accounting for 7 to 30% of all cases. Operational criteria for the antemortem clinical diagnosis of SDLT have already been proposed by our group. The performance of these is now examined by randomizing the case notes from a new series of SDLT, Alzheimer, and multi-infarct dementia patients for psychiatric assessment by four raters of varying clinical experience and blind to pathologic diagnosis. Using the SDLT criteria, the two most experienced raters agreed in 94% of cases (kappa = 0.87), with the least experienced rater agreeing in 78% (kappa = 0.50). Diagnostic specificity for SDLT was uniformly high (90.0 to 97.0%), with a mean sensitivity of detection of 74%, and was greater by the experienced (90.0%) than the least experienced (55%) clinician. The antemortem identification of SDLT patients can therefore be achieved with a high degree of diagnostic specificity using such operationalized criteria, although there remains a minority of patients who present with either "typical" Alzheimer-type symptoms or with paranoid or delusional symptoms in the absence of substantial cognitive impairment. Sensitivity to neuroleptics may be a useful diagnostic pointer in these patients.

Entities:  

Mesh:

Year:  1994        PMID: 8190290     DOI: 10.1212/wnl.44.5.872

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging.

Authors:  R Barber; P Scheltens; A Gholkar; C Ballard; I McKeith; P Ince; R Perry; J O'Brien
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

Review 2.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

3.  Association between medial temporal lobe atrophy on CT and parietotemporal uptake decrease on SPECT in Alzheimer's disease.

Authors:  I Lavenu; F Pasquier; F Lebert; B Jacob; H Petit
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 4.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

5.  Comparative analysis of cognitive impairments in lewy body dementia and Alzheimer's disease.

Authors:  I S Preobrazhenskaya; E A Mkhitaryan; N N Yakhno
Journal:  Neurosci Behav Physiol       Date:  2006-01

Review 6.  Parkinsonism--recognition and differential diagnosis.

Authors:  N Quinn
Journal:  BMJ       Date:  1995-02-18

7.  Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography.

Authors:  Z Walker; D C Costa; A G Janssen; R W Walker; G Livingstone; C L Katona
Journal:  Eur J Nucl Med       Date:  1997-06

8.  Extrapyramidal examinations in psychiatry.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Innov Clin Neurosci       Date:  2012-07

9.  Trajectory of white matter hyperintensity burden preceding mild cognitive impairment.

Authors:  Lisa C Silbert; Hiroko H Dodge; Louie G Perkins; Lena Sherbakov; David Lahna; Deniz Erten-Lyons; Randall Woltjer; Lynne Shinto; Jeffrey A Kaye
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

Review 10.  Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.

Authors:  Dhiren Singh; Daniel W O'Connor
Journal:  Clin Interv Aging       Date:  2009-09-01       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.